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The antioxidative enzyme thioredoxin reductase (TrxR) has been suggested to be a drug target in several
pathogens, including the protist parasite Giardia lamblia. TrxR is also believed to catalyse the reduction of
nitro drugs, e.g. metronidazole and furazolidone, a reaction required to render these compounds toxic to
G. lamblia and other microaerophiles/anaerobes. It was the objective of this study to assess the potential
of TrxR as a drug target in G. lamblia and to ﬁnd direct evidence for the role of this enzyme in the
activation of metronidazole and other nitro drugs.
TrxR was overexpressed approximately 10-fold in G. lamblia WB C6 cells by placing the trxR gene
behind the arginine deiminase (ADI) promoter on a plasmid. Likewise, a mutant TrxR with a defective
disulphide reductase catalytic site was strongly expressed in another G. lamblia WB C6 cell line. Sus-
ceptibilities to ﬁve antigiardial drugs, i.e. metronidazole, furazolidone, nitazoxanide, albendazole and
auranoﬁn were determined in both transfectant cell lines and compared to wildtype. Further, the impact
of all ﬁve drugs on TrxR activity in vivo was measured.
Overexpression of TrxR rendered G. lamblia WB C6 more susceptible to metronidazole and furazoli-
done but not to nitazoxanide, albendazole, and auranoﬁn. Of all ﬁve drugs tested, only auranoﬁn had an
appreciably negative effect on TrxR activity in vivo, albeit to a much smaller extent than expected.
Overexpression of TrxR and mutant TrxR had hardly any impact on growth of G. lambliaWB C6, although
the enzyme also exerts a strong NADPH oxidase activity which is a source of oxidative stress.
Our results constitute ﬁrst direct evidence for the notion that TrxR is an activator of metronidazole and
furazolidone but rather question that it is a relevant drug target of presently used antigiardial drugs.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Giardia lamblia (syn duodenalis, intestinalis) is a microaerophilic
protist parasite that occurs in all parts of the world and infects
hundreds of millions of people every year (Centers for Disease
Control and Prevention, CDC). It colonizes the small intestine
and causes gastrointestinal symptoms like nausea, diarrhea,
bloating and malabsorption of nutrients. Although not life-
threatening in most cases, Giardia infections can be persistent
and cause growth retardation in children (Buret, 2008). Treatment
mainly relies on 5-nitroimidazoles, such as metronidazole
and tinidazole, or albendazole, a benzimidazole drug (Leitsch,etsuisse Faculty, University of
d.
D. Leitsch).
Ltd on behalf of Australian Society f2015). 5-nitroimidazoles have been in use against practically all
microaerophilic or anaerobic pathogens for more than 50 years
due to the comparably low rate of resistance (Leitsch, 2015).
However, metronidazole-resistant microaerophiles and anaer-
obes, including isolates of G. lamblia, do occur. Due to the impor-
tance of 5-nitroimidazoles, especially metronidazole which is
listed among the “essential medicines” by the WHO (World Health
Organisation, 2015), a large number of studies on 5-nitroimidazole
action and resistance have been conducted throughout the last 30
years.
5-Nitroimidazoles are essentially prodrugs and not very reac-
tive. Reduction at the nitro group, however, activates nitro-
imidazoles which react with numerous cell constituents - in G.
lamblia e.g. DNA (Uzlikova and Nohynkova, 2014), proteins (Leitsch
et al., 2012), and thiols (Leitsch et al., 2012). Due to the extremely
low reduction potential of 5-nitroimidazoles reduction at the nitro
group occurs quantitatively only in microaerophilic and anaerobicor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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Entamoeba histolytica and Trichomonas vaginalis, several enzymatic
pathways were identiﬁed that are likely to play a role in 5-
nitroimidazole reduction, including the central metabolic enzyme
pyruvate:ferredoxin oxidoreductase (PFOR) together with ferre-
doxin (Townson et al., 1996; Rasoloson et al., 2002; Leitsch et al.,
2011) and thioredoxin reductase (TrxR) (Leitsch et al., 2007, 2009;
2011), a central redox regulator. Further, another 5-nitroimidazole
reducing enzyme, nitroreductase 1 (NR1), was identiﬁed in G.
lamblia (Müller et al., 2007). A correlation between expression
levels of nitroreductase 1 and PFOR/ferredoxin and metronidazole
sensitivity in G. lamblia is well documented, as PFOR and nitro-
reductase 1 are less strongly expressed in many metronidazole-
resistant cell lines (Müller et al., 2008; Leitsch et al., 2011). More-
over, overexpression of NR1 from a plasmid renders G. lambliamore
sensitive tometronidazole (Nillius et al., 2011). Direct evidence for a
role of TrxR in 5-nitroimidazole reduction in vivo, however has
been missing so far.
Importantly, TrxR was not only found to reduce 5-
nitroimidazoles but also to be targeted by reduced nitroimidazole
intermediates (Leitsch et al., 2007, 2009; 2011), resulting, at least in
E. histolytica (Leitsch et al., 2007) and T. vaginalis (Leitsch et al.,
2009), in a diminished thioredoxin reducing activity of the
enzyme (Leitsch et al., 2007, 2009). Thus, TrxR has an intriguing
double role as an activator and target of 5-nitroimidazoles. It was
hypothesised that inhibition of TrxR could be one of the major toxic
effects brought about by 5-nitroimidazoles (Leitsch et al., 2007,
2009). The TrxR/thioredoxin (Trx) redox system has multiple
roles in most organisms, including reduction of peroxiredoxins
and maintaining the activity of enzymes like ribonucleotide
reductase and methionine sulfoxide reductase. In G. lamblia, how-
ever, the role of the TrxR/Trx system is still poorly understood.
Although G. lamblia TrxR displays marked disulphide reduction and
NADPH oxidase activities (Tejman-Yarden et al., 2013), a functional
thioredoxin has not be identiﬁed so far (Leitsch et al., 2011;
manuscript in preparation). Further, several enzymes known to
be dependent on thioredoxin-mediated reduction, such as ribo-
nucleotide reductase, are absent from the parasite. However,
despite the current lack of knowledge about the physiological role
of TrxR it is generally believed to be an important target not only of
metronidazole (Leitsch et al., 2012) but also of auranoﬁn, an anti-
rheumatic drug that has been reproﬁled for off-label use against G.
lamblia (Tejman-Yarden et al., 2013) and E. histolytica (Debnath
et al., 2012).
In order to evaluate the role of TrxR as an activator of anti-
giardial drugs and as a drug target, expression levels of the enzyme
were strongly increased in G. lamblia trophopzoites by transfection
of an episomal copy of the TrxR gene under control of the arginine
deiminase (ADI) promoter. Likewise, a dominant negative mutant
of the TrxR gene under control of the ADI promoter was introduced.
Transfectants were assayed for altered drug susceptibilities and
used for enzyme inhibition assays.2. Materials and methods
2.1. Chemicals
Metronidazole, furazolidone, nitazoxanide, auranoﬁn and
albendazole were purchased from Sigma (St. Louis, Mo, USA). All
drugs tested are depicted in Fig. 1. Growth medium constituents
were purchased from Merck (peptone from casein, yeast extract,
sodium chloride, glucose, ammonium iron (III) citrate). Fetal calf
serum was purchased from Biochrom (Bioswisstec AG, Schaffhau-
sen, Switzerland).2.2. Cell culture
G. lamblia WB C6 (ATCC 50803) trophozoites were axenically
cultivated in Keister's modiﬁed Diamond's medium. Media were
sterile-ﬁltered. Subcultures were performed every third day.
2.3. Construction of a TrxR overexpressing transfectant
The TrxR gene (GL50803_9827; XM_001707116) was ampliﬁed
from genomic DNA isolated from WB C6 (ATCC 50803) with
primers bearing 50 bp of the upstream region and 50 bp of the
downstream region, respectively, of the arginine deiminase gene
(GL50803_112103; XM_001705703), and PacI and XbaI restriction
sites for cloning into the pPac-VInteg vector (Stefanic et al., 2009).
The primer sequences were as follows: (forward) CATCTA-
GAAACGTCTACACGTGAGGTG TGTAAACTTCCGGAGAAAAAAATCCTA
GTACATGTCTGCTCAAGCATTCGA, (reverse) CATTAATTAAC TGGA-
TATGAACATGTCAATTATTTGATATCTGAATTACAATTCACTGTTTTAGT
GATGGTGATGGTGAT. Transfections of the new plasmid pTrxR
into WB C6 trophozoites were performed in a BTX Electro
cell manipulator 600 (Harvard Apparatus) with the settings
500 V, 800 mF, and 720 U. Transfectant WB C6 cells were selected
via the plasmid-encoded puromycin N-acetyl-transferase (pac)
gene by adding puromycin to the growth medium (100 mg/l). The
plasmid constructs are schematically depicted in Supplementary
Fig. 1.
2.4. Construction of an episomal mutagenized TrxR gene
The second cysteine of the active site of TrxR on pTrxR was
mutated to serine using the QuikChange II XL Site-Directed Muta-
genesis kit (Agilent) according to the manufacturer's instructions.
The mutagenesis primers introduced one single nucleotide ex-
change in order to alter a cysteine codon (TGC) to a serine codon
(AGC). The sequences of the primers were as follows: (forward)
GTCGGCCTGCGCTGTCAGCGATTCTGC, (reverse) GCAGAATCGCTGA-
CAGCGCAGGCCGAC. The resulting plasmid pTrxR-mut was trans-
fected into WB C6 as described above.
2.5. Two-dimensional gel electrophoresis of G. lamblia protein
extracts (2DE)
Two-dimensional gel electrophoresis (2DE) with G. lamblia cell
extracts was performed as described previously (Leitsch et al., 2011,
2012). Gels were stained with Coomassie Blue R-250 and evaluated
using Melanie™ 4 software (Genebio).
2.6. mRNA quantiﬁcation of expression by real-time RTePCR
For quantiﬁcation of TrxR mRNA expression, cells were har-
vested as described above and RNA was extracted using a Qiagen
RNeasy Kit (Qiagen, Hilden, Germany). Synthesis of ﬁrst-strand
cDNA was performed using a Qiagen OmniscriptRT Kit (Qiagen).
The primers used for the ampliﬁcation of a 189 bp TrxR gene
fragment: (forward) CGTTGGCCACGATCCCC, (reverse) GGGGATC
GTGGCCAACG. TrxRmRNA levels were calculated using actinmRNA
as internal standard (primers: ACTquantF, ACATATGAGCTGCCA-
GATGG; ACTquantR TCGGGGAGGCCTGCAAAC).
Quantitative RTePCR was performed on a LightCyclerTM In-
strument (Roche Diagnostics, Rotkreuz, Switzerland) as described
previously (Nillius et al., 2011). Expression levels of TrxR mRNA
were calculated as arbitrary units in relation to the quantity of actin
mRNA. PCRs were performed in triplicate in three independent
experiments.
Fig. 1. The ﬁve antigiardial drugs tested in this study. 1, metronidazole; 2, furazolidone; 3, nitazoxanide; 4, albendazole, and 5, auranoﬁn.
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Culture medium (10 ml) was inoculated with 10,000 tropho-
zoites/ml and drugs were added in appropriate amounts. After in-
cubation (37 C, 48 h), cell numbers were determined in a Bürker-
Türk chamber and IC50 values were calculated using Graﬁt 7 soft-
ware (Erithacus software). The generation times of the cell lines
were determined in duplicates in three independent biological
replicates applying identical inoculates and incubation conditions.
2.8. Nitroreductase assay
5 mg/mL recombinant G. lamblia TrxR and 100 mM of either
furazolidone or nitazoxanide were added to Tris pH 7.5 buffer,
containing 1 mM EDTA, 0.5 mM NADPH and 50 mM cytochrome c
(Leitsch et al., 2011). Reduction of cytochrome c (Sigma, St. Louis,
Mo, USA) was measured in a Lambda 25 UV/Vis spectrometer
(Perkin Elmer) at l¼ 550 (Dε550¼ 20mM1 cm1). Recombinant G.
lamblia TrxR was expressed and puriﬁed as described (Leitsch et al.,
2011).
2.9. Disulphide reductase and NADPH oxidase assays with
G. lamblia cell extracts
Disulphide reductase and NADPH oxidase activities of TrxRwere
measured photometrically using cell extracts of the respective G.
lamblia cell lines. Cells were harvested and lysed by resuspension of
the pellet in 10 times the volume of ultrapurewater. Cell debris was
removed (20,000  g for 10 min) and protein concentrations of the
supernatants determined by Bradford assay. 50 mg protein/mL were
used in all measurements. Disulphide reductase activity in G.
lamblia extracts was measured at 37 C by quantifying reduction of
DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) to TNB (2-nitro-5-
thiobenzoate) at l ¼ 412 (Dε412 ¼ 13.6 mM1 cm1) in 100 mM
Tris pH 7.5 buffer containing 0.5mMNADPH,1mM EDTA and 1mM
DTNB (Merck). Net TrxR activity without background reduction of
DTNB by thiols and proteins was calculated by adding 10 mM of the
non-competitive ﬂavin inhibitor diphenyleneiodonium (DPI).
NADPH oxidase activity was measured in 100mM Tris pH 7.5 buffer
containing 0.2 mM NADPH and 1 mM EDTA by determiningoxidation of NADPH at l ¼ 340 (Dε340 ¼ 6.2 mM1 cm1). Again,
10 mM DPI were added in order to determine the net NADPH oxi-
dase activity of TrxR.
2.10. Western blotting
Polyclonal antibodies were raised in rabbit against G. lamblia
TrxR (GenicBio Biotech, Shanghai, China). Sera were diluted 1:1000
for the detection of TrxR on western blots of G. lamblia cell extracts
using anti-rabbit IgG (Sigma-Aldrich; 1:5000). Western blotting
was performed according to standard protocols.
3. Results
3.1. Generation of TrxR overexpressing transfectant WB C6 lines
In order to assess the role of TrxR in the reduction of metroni-
dazole and other drugs containing a nitro group, an expression
construct based on pPAV-VInteg (Stefanic et al., 2009) was devised
for the manipulation of TrxR expression levels in G. lamblia. Pre-
liminary experiments harnessing 2DE and RT-qPCR had shown that
episomal expression of the TrxR gene under its own promoter did
not result in recognisable higher copy numbers of TrxR protein and
mRNA, respectively (data not shown). The position of TrxR in 2DE
gels had been identiﬁed earlier (Leitsch et al., 2011) and was hence
known to us at the start of the study. Several promoters of very
highly expressed proteins were tested as replacement of the trxR
promoter on the plasmid, including 50 bp of the upstream and
downstream regions, respectively, of the arginine deiminase (ADI)
gene, one of the most strongly expressed proteins in G. lamblia as
recognisable on 2DE gels (Supplementary Fig. 2). The resulting
vector was named pTrxR and transfected into G. lamblia WB C6
trophozoites. Transfectants bearing pTrxR (WB TrxR) had an
approximately 10-fold higher expression level of TrxR (Fig. 2) than
wildtype WB C6, rendering TrxR one of the most prominent pro-
teins in 2DE gels. The elevated expression level of TrxR inWB pTrxR
was further conﬁrmed in a western blot assay using an anti-TrxR
antibody (Supplementary Fig. 3). The increase in protein levels
was mirrored by strong increases of TrxR mRNA levels (Table 1). In
order to check whether TrxR was functional inWB TrxR, disulphide
Fig. 2. Sections of 2D-gels from cell extracts of G. lambliaWB C6 without plasmid (wildtype), with a plasmid harbouring the trxR gene behind the ADI promoter (WB TrxR), and with
a plasmid harbouring a mutated trxR gene behind the ADI promoter (WB TrxR-mut). TrxR is encircled. The degree of overexpression of TrxR (functional or mutated) in relation to
wildtype is indicated beneath the gel sections. The gel shown is representative for three biological replicates in total.
Table 1
Expression of TrxR at the mRNA and protein levels in WB TrxR and WB TrxR-mut as compared to wildtype WB C6, and resulting changes in disulphide reductase and NADPH
oxidase activities in these cell lines.
TrxR expression Relative expression
level (protein)
Relative expression
level (mRNA)
Disulphide reductase
activity in cell extract
(nmol min1 mg1)
NADPH oxidase activity in cell
extract (nmol min1 mg1)
WB C6 (wildtype) 1 1 10.2 ± 1.5 27 ± 7
WB TrxR 10 25 105 ± 14 213 ± 17
WB TrxR-mut 6.5 11 12.1 ± 2.3 278 ± 27
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cell extracts. Indeed, WB TrxR displayed approximately tenfold
disulphide reductase and NADPH oxidase activities as compared to
wildtype (Table 1). It is important to note that disulphide reductase
activity in wildtype cells was low and difﬁcult to measure because
background reduction of DTNB by cell constituents of the added
extract was several times higher. Another expression construct was
designed that placed a mutated TrxR gene behind the ADI pro-
moter. To this end the second cysteine of the enzyme's active site
was mutated to serine which nulliﬁes disulphide reductase activity
because thioredoxin reductases require two cysteines in their
active site to reduce disulﬁde bonds in the substrate (Schlosser
et al., 2013). Mutant TrxR could be overexpressed from pTrxR-
mut in WB C6 trophozoites (WB TrxR-mut) to levels comparable
to those in WB TrxR but disulphide reductase activity was practi-
cally identical to wildtype (Fig. 2, Table 1). NADPH oxidase activity,
however, was even slightly higher (p < 0,05) in WB TrxR-mut than
in WB TrxR (Table 1). When 10 mM of the ﬂavin inhibitor diphe-
nylene iodonium (DPI) were added to reactions, both disulphide
reductase and NADPH oxidase activities were completely inhibited,
showing that NADPH oxidase activity is independent of the cata-
lytic cysteines but requires the cofactors NADPH and FAD. Impor-
tantly, the very high expression levels of native TrxR and mutant
TrxR did hardly, if at all, affect growth of the transfected cell lines in
G. lamblia growth medium although the at least tenfold NADPHTable 2
IC50 values determined for wildtype WB C6, WB TrxR, and WB TrxR-mut for all ﬁve
drugs. Asterisks indicate statistically signiﬁcant differences to wildtype (unpaired t-
test, two sided; *P < 0.01; **P < 0.05). ND… not determined.
Drug IC50
Wild type WB TrxR WB TrxR-mut
Metronidazole (mM) 3.44 ± 0.06 2.33 ± 0.03* 3.71 ± 0.36
Furazolidone (mM) 0.73 ± 0.04 0.52 ± 0.03** 0.79 ± 0.02
Nitazoxanide (mM) 1.86 ± 0.05 1.63 ± 0.04 1.76 ± 0.03
Albendazole (nM) 59.3 ± 0.4 60.8 ± 0.4 59.9 ± 1.4
Auranoﬁn (mM) 16.5 ± 1 16.8 ± 0.1 NDactivity would be expected to cause considerable oxidative stress
through generation of superoxide radicals. Still, wildtype WB C6
displayed practically the same generation time (410 ± 10 min) as
WB C6 pTrxR (435 ± 15min) andWB C6 pTrxR-mut (430 ± 10min).
Further, no effect of altered TrxR levels on motility or shape could
be observed under the light microscope. WB TrxR-mut was used as
a control in the ensuing drug susceptibility assays in order to
demonstrate that increased nitroreductase activity of the enzyme
and not overexpression of the enzyme by itself is responsible for
altered drug susceptibilities.3.2. Evaluation of G. lamblia TrxR as an activator of and target of
antigiardial drugs
Five antigiardial drugs (Fig. 1) were selected for susceptibility
testing in the transfected cell lines: the 5-nitroimidazole metroni-
dazole, the 5-nitrofuran furazolidone, the nitrothiazolide nitazox-
anide, the benzimidazole albendazole, and auranoﬁn. The ﬁrst
three drugs have nitro groups which need to be reduced for activity
(Müller et al., 2007; Leitsch, 2015) and are thus potential substrates
for TrxR. Albendazole, however, lacks a nitro group and does not
require reduction for toxicity. Also Auranoﬁn, a novel antigiardial
drug known to semicompetitively inhibit TrxR in vitro (Tejman-
Yarden et al., 2013), lacks a nitro group. Thus, prior to the suscep-
tibility assays we hypothesised that WB TrxR would be more sus-
ceptible to the three nitro drugs but less susceptible to auranoﬁn,
due to much higher concentrations of the target molecule, i.e. TrxR.
Susceptibility to albendazole was expected to be unchanged in WB
TrxR.
Indeed, overexpression of TrxR had no inﬂuence on the sus-
ceptibility to albendazole (Table 2). In contrast to our prediction,
however, overexpression of TrxR did not confer more tolerance to
auranoﬁn but had no effect at all (Table 2). In accordance with
TrxR's capacity to function as a nitroreductase, however, over-
expression of functional TrxR rendered WB TrxR more sensitive to
metronidazole and furazolidone (Table 2) than wildtype or WB
TrxR-mut. Surprisingly, the effect of TrxR overexpression was not
Table 3
Recombinant G. lamblia TrxR as a nitroreductase with the substrates metronidazole,
furazolidone, and nitazoxanide. *already published in Leitsch et al., 2011.
Drug Reduction by G. lamblia TrxR
Metronidazole (1 mM) 81 ± 30 nmol min1 mg1*
Furazolidone (100 mM) 1094 ± 25 nmol min1 mg1
Nitazoxanide 0
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group which was shown to be essential for toxicity (Müller et al.,
2007). In order to check whether nitazoxanide is a potential sub-
strate for G. lamblia TrxR, we used puriﬁed recombinant G. lamblia
TrxR for measuring reduction of nitazoxanide along the lines
described for metronidazole and other 5-nitroimidazoles in an
earlier study (Leitsch et al., 2011). Indeed, no nitroreductase activity
of recombinant TrxR activity could be observed with nitazoxanide
as substrate (Table 3). In contrast, furazolidone, was strongly
reduced by recombinant G. lamblia TrxR (Table 3). This suggests
that the elevated expression levels of TrxR in WB TrxR are
responsible for a higher susceptibility to metronidazole and fura-
zolidone, whereas the susceptibility to nitazoxanide remains un-
changed because it is not a substrate of TrxR.
As a second step we delineated the role of TrxR as a drug target
and assessed the effect of the ﬁve drugs on disulphide reductase
activity of TrxR in WB TrxR (Fig. 3). Inhibition of TrxR by metroni-
dazole and furazolidone was not signiﬁcant, whereas nitazoxanide
and albendazole did not inhibit TrxR at all (Fig. 3). Auranoﬁn was
the only drug that substantially reduced disulphide reductase ac-
tivity of TrxR in WB TrxR (Fig. 3). When applied at 20 mM auranoﬁn
reduced TrxR activity to 60% as compared to control but even at a
concentration of 50 mM,which is about the 300-fold dose of the IC50
as determined with recombinant G. lamblia TrxR in vitro (Tejman-
Yarden et al., 2013), residual activity of TrxR in WB TrxR did not
drop below 40% as compared to untreated WB TrxR. This indicates
that the dose-response curve is rather ﬂat and that even much
higher concentrations of auranoﬁn would not reduce TrxR activity
in WB TrxR below the rate as observed in wildtype (Fig. 3). Indeed,
TrxR activity in WB TrxR treated with 50 mM auranoﬁn, was still
4e5-fold higher than in untreatedwildtype (Fig. 3), at least after 2 h
of incubation. Our results demonstrate that TrxR is a target of
auranoﬁn in the living parasite. It is not likely, however, that TrxR isFig. 3. Impact of the drugs tested on disulphide reductase activity of TrxR in cell extracts
activities from untreated wildtype and wildtype treated with auranoﬁn are given for compa
WB TrxR (paired t-test, two sided; *P < 0.05).a critical target of auranoﬁn in G. lamblia since the susceptibility of
WB TrxR to auranoﬁn is equal to that of wildtype (Table 2). In fact,
the results of this experiment suggest that G. lamblia TrxR is not a
relevant target of any drug presently used for the treatment of
giardiasis.
4. Discussion
We devised a plasmid-based expression construct that coupled
the trxR gene to the ADI promoter, resulting in approximately
tenfold higher intracellular concentrations of the enzyme as
compared to wildtype. Overexpression of TrxR rendered G. lamblia
more susceptible to metronidazole and furazolidone (Table 2), two
drugswhich are reduced by recombinant TrxR in vitro (Leitsch et al.,
2011) (Table 3). Although indirect evidence for the reduction of
metronidazole in vivo by TrxR had already been presented for E.
histolytica (Leitsch et al., 2007), T. vaginalis (Leitsch et al., 2009), and
G. lamblia (Leitsch et al., 2007), this study constitutes ﬁrst direct
evidence that TrxR is an activator of nitro drugs in the living
parasite. It can be ruled out that the higher susceptibility of WB
TrxR to metronidazole and furazolidone was due to a decreased
ﬁtness caused by overexpression of TrxR as such because the sus-
ceptibilities to the other drugs tested were unaltered. Further, TrxR
had to be functional in order to render WB C6 more susceptible to
metronidazole and furazolidone (Table 2), as overexpression of
mutated TrxR in WB TrxR-mut did not result in increased sensi-
tivity to metronidazole and furazolidone (Table 2). Finally, since
NADPH oxidase activity in WB TrxR-mut was even higher than in
WB TrxR, it can be also ruled out that TrxR indirectly renders G.
lamblia more susceptible to metronidazole and furazolidone by
causing oxidative stress through generation of superoxide radicals.
It is evident, however, that the effect of TrxR overexpression on
metronidazole and furazolidone susceptibility was only moderate.
This ﬁnding is in line with the notion that several factors contribute
to nitro drug reduction in G. lamblia and other microaerophilic
parasites. One well documented example is nitroreductase 1 from
G. lamblia which, when overexpressed, increases susceptibility to
metronidazole quite to the same extent as shown here for TrxR
(Nillius et al., 2011; reviewed in Leitsch, 2015).
Surprisingly, the direct effect of four of the ﬁve drugs on TrxR
activity was minute, if at all measurable. Only auranoﬁn, a com-
pound known to inhibit G. lamblia TrxR effectively in vitro alsoof WB TrxR after 2 h of treatment. Untreated WB TrxR represents 100% activity. TrxR
rison. Asterisks indicate statistically signiﬁcant differences to TrxR activity in untreated
D. Leitsch et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 148e153 153inhibited TrxR in vivo to a relevant extent (Fig. 3). Still, even if
auranoﬁn was applied in very high concentrations (50 mM) the
residual TrxR activity was still 4 to 5-times higher than in untreated
wildtype (Fig. 3). Since wildtype and WB TrxR were equally sus-
ceptible to auranoﬁn (Table 2), we conclude that TrxR, quite in
contrast to the commonly held belief (Tejman-Yarden et al., 2013;
Watkins and Eckmann, 2016), is not the primary target of this
drug in G. lamblia.
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